$Avalo Therapeutics (AVTX.US)$
Poor Performance So Far
Over the past few weeks, we have seen a lot of unusual activity in this ticker symbol. If there is anyone out there who knows why activity has picked up in AVTX, then please enlighten me.
Over the past few years, putting money into this company has been losing bet. Any stock that is in a long-term downtrend is usually something that I would stay away from.
Intriguing Technical Developmemts
Over the past few weeks,...

By Julianna
Investors appear to be losing patience with Ark Investment Management's genomics fund.
$ARK Genomic Revolution ETF (ARKG.US)$ is an actively managed ETF that focus on health care, information technology, materials, energy, and consumer discretionary.
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.
- according to ARKG fund description.
However, ARKG is down 30% this year as investors shun health-care stocks in favor for more cyclical names that perform well during an economic recovery. Even so, this ETF is faring far worse than the broader biotech sector, with the $Dow Jones U.S. Biotechnology Index (.DJUSBT.US)$up 11.35% this year.
ARKG is currently trading at $65.16 a share, 43% lower from its peak in this February. The genomics fund has also seen the largest outflows among Ark's ETFs this year.
It's interesting that typically loyal Ark investors have been bailing on the ETF.
The fund's assets have been chopped in half since February. While I don't believe the ETF is experiencing some of sort of 'doom loop,' clearly the outflows are putting downward price pressure on the underlying holdings and testing the will of remaining fund owners.
- said Nate Geraci, president of The ETF Store, an advisory firm.
FOLLOW ME to know more about ETFs
PLZ leave your comments and likes below
ARKG's top two holdings, $Teladoc Health (TDOC.US)$and $Exact Sciences (EXAS.US)$, heavily impact its performance, with drops of 47% and 33.5% this year, respectively.
The recent outflows may be due to investors looking for shorter-term opportunities into the year-end and freeing up cash.
- said Sylvia Jablonski, chief investment officer at Defiance ETFs.
Ark Chief Executive Officer Cathie Wood is well-known for prioritizing longer term investments over short-term gains.
This is a 5-10 year hold. AI in health care is going to change the way that we can predict, treat and manage the most difficult diseases like cancer, and the Ark fund gives investors access to the companies who are on the cutting edge of that research.
- Jablonski added.
Have you ever invested in the Biotechnology sector? Do you agree with Jablonski's opinion?
Source: Bloomberg